Understanding Chaos & the Limits of Control
Human-designed systems that attempt to steer complex and interdependent natural or social phenomena often underestimate their own blind spots. Three systems especially: the macroeconomy, human physiology (especially the brain), and the global climate. Each has massive numbers of inputs and outputs, feedback loops, threshold effects, uncertain variables. Because of this, even with good intentions, interventions can misfire, produce unintended consequences, or simply fail due to oversimplification.
We’ll focus here on two: Big Pharma (physiology / medicine) and climate modeling (for climate intervention & prediction), because they illustrate how complex systems resist clean fixes.
Big Pharma: Risks, Side Effects, and Structural Flaws
-
Complexity of physiology & brain
-
The human body, especially the brain, is not a simple mechanical system. Many drugs act on multiple pathways, with side effects that are hard to predict due to individual differences (genetics, existing conditions, environment).
-
The so-called “prescription cascade” is one such feedback loop: a drug causes a side effect → that side effect is misdiagnosed → additional drugs are prescribed → which have their own side effects → and the cycle continues. (Wikipedia)
-
-
Eroom’s Law: Innovation is slowing, costs rising
-
Drug development has become slower and more expensive over time, despite technological and scientific advances. This suggests diminishing returns in how effectively humans are mastering/controlling human physiology. (Wikipedia)
-
-
Bias, suppression & influence
-
Clinical trials funded by Big Pharma often show bias. Companies sometimes suppress negative trial results, or promote favorable results more heavily. (Drugwatch.com)
-
Example: Vioxx (Merck) had safety signals regarding heart attack risk that were under-communicated initially. Later it was withdrawn after harm became clear. (Drugwatch.com)
-
-
Profit incentives misaligned with full understanding
-
Pharmaceutical companies are incentivized by market size, patent protection, speed to market; less rewarded for understanding long-term interactions, rare side effects, or non-drug (lifestyle / preventive) interventions.
-
Some critics argue Big Pharma emphasizes symptom control rather than curing disease, because chronic treatments are more profitable. (Boomer Blooms)
-
-
Regulation & bottlenecks
-
Regulatory systems try to help, but also rely on the data and reporting companies supply. If data are biased or incomplete, regulators may be misled.
-
Interactions between multiple medications, rare side effects, long latency periods (e.g., cancers or neurological damage) are often only discovered after widespread use.
-
Climate Models: Strengths, Uncertainties, & Overconfidence
-
Model structure & parameter uncertainty
-
Climate models (GCMs and earth-system models) simplify or parameterize many complicated processes: clouds, aerosol interactions, feedbacks (cloud-aerosol, water vapor, albedo, etc.). These simplifications introduce structural uncertainty. (das-wissen.de)
-
For example, cloud behavior is notoriously hard to model; small changes in cloud cover, altitude, optical thickness can produce large radiative forcing shifts. (Planetary P&L)
-
-
Forcing uncertainties
-
Inputs like how much past volcanic activity, solar irradiance (especially UV spectrum), aerosol loadings (from both natural and human sources) have contributed, are not precisely known. Uncertainties here propagate through the model. (PNAS)
-
Small errors in “forcing” assumptions (e.g. aerosol cooling, solar variability) lead to significant divergence in projections. (PNAS)
-
-
Resolution & coarse approximations
-
Many global models use large grid cells; local features (mountains, coastlines, small-scale convection, urban heat islands) are often underrepresented. These local effects can matter for predicting extreme events or regional climate changes. (das-wissen.de)
-
-
Natural variability & feedback loops
-
Climate has internal variability (e.g., El NiƱo, decadal oscillations) and multiple feedback loops which can amplify or damp effects in non-linear ways. Predicting tipping points is extremely difficult.
-
Example: uncertainties in how clouds respond to warming (positive vs negative feedback), or how much polar albedo will change. (Planetary P&L)
-
-
Scenario dependence & policy risk
-
Projections are often conditional on scenarios of human behavior (greenhouse gas emissions, land use, population growth). These are uncertain and highly variable.
-
Overconfidence in a single model or scenario may mislead policy; underestimation of worst-case or unmodeled risk can lead to ill-preparedness.
-
Synthesis & Moral of the Story: Hubris & Humility
Given these complexities, there’s a strong case that many proposed “solutions” to physiological or environmental issues carry risk of unanticipated negative outcomes. The common thread in both Big Pharma and climate modeling:
-
Hubris: assuming sufficient understanding of the system to safely intervene or optimize; neglecting rare interactions, feedbacks, unmeasured variables.
-
Overconfidence in models or cause-and-effect: believing models are more predictive than they are; thinking side effects or indirect consequences are manageable when they may be poorly understood.
-
Neglected caution and humility: using pilot, incremental, reversible interventions; monitoring; admitting uncertainty; allowing space for error.
Implications & Guidelines for Responsible Action
Here are principles one might adopt, given acceptance of these limitations:
-
Precautionary approach: Intervene gradually, monitor outcomes, be ready to reverse course.
-
Transparency & independent verification: Clinical trial data, climate model inputs, and uncertainties should be openly shared; third-party replication and critique encouraged.
-
Emphasis on robustness over optimization: Instead of trying to “perfect” or “optimize” a system, aim for policies resilient to uncertainty, that perform acceptably under many possible futures.
-
Local adaptation & context sensitivity: Solutions should be adapted to local physiological, cultural, and environmental conditions; what works in one population or region may not in another.
-
Plurality of models & voices: Encourage multiple modeling approaches or competing hypotheses; discourage monopoly of one paradigm.
Conclusion
The economy, human physiology (especially medicine), and global climate are chaotic systems with high dimensionality, feedback loops, and large uncertainties. Big Pharma sometimes overreaches in treating body and mind, underestimating complexity, suppressing negative data, or pushing profit over caution. Climate models, while powerful tools, rely on imperfect knowledge of forcings, coarse approximations, parameter choices, and face natural variability that is difficult to fully capture. Recognizing these limits isn’t an excuse for inaction, but a call for humility, rigorous evidence, incremental intervention, and caution.
Comments
Post a Comment